Apolipoprotein A-I

Updated: Jul 07, 2021
  • Author: Georges Elhomsy, MD, ECNU, FACE; Chief Editor: Eric B Staros, MD  more...
  • Print

Reference Range

Apolipoprotein A-I (Apo-A1) is a structural and functional protein that constitutes approximately 70% of the protein in high density lipoprotein (HDL).

The reference ranges of Apo-A1 are as follows [1] :

  • Adult males: 75-160 mg/dL
  • Adult females: 80-175 mg/dL
  • Male newborns: 41-93 mg/dL
  • Female newborns: 38-106 mg/dL
  • Males (aged 6 months-4 years): 67-167 mg/dL
  • Females (aged 6 months-4 years): 60-148 mg/dL
  • Children aged 5-17 years: 83-151 mg/dL
Next:

Interpretation

Low apolipoprotein A-I level

A low Apo-A1 level indicates an increased risk of cardiovascular disease, especially in the presence of an elevated apolipoprotein B (Apo-B) level. [2, 3, 4, 5]

Other factors that are associated with low Apo A1 level include the following:

High apolipoprotein A-I level

High Apo-A1 levels are associated with the following:

  • Pregnancy

  • Alcohol use

  • Spring and summer seasons [6]

Previous
Next:

Collection and Panels

Patient instructions: Overnight fasting (12-14 hours)

Collection tube: Lavender top (EDTA)

Unacceptable conditions: Hemolyzed specimens

Specimen preparation: Separate serum from cells as soon as possible or within 2 hours of collection and transfer to 1-mL serum transport tube

Storage/transport temperature: Refrigerated

Stability refrigerated: 8 days unfrozen; 3 months frozen

Panels: None

CPT Code: 82172

Previous
Next:

Background

Description

Apolipoprotein A-I (Apo-A1) is a structural and functional protein that constitutes approximately 70% of the protein in HDL.

Apo-A1 is produced in the liver and intestines and activates lecithin-cholesterol acyltransferase (LCAT) in the peripheral tissues, which transforms free cholesterol to cholesterol ester and facilitates its transportation to the liver, were it is degraded.

Indications/Applications

Because it is not clear whether Apo-A1 is an independent predictor of cardiovascular disease, it may be useful for Apo-A1 to be measured in conjunction with Apo-B to assess the Apo-B/Apo-A1 ratio.

A higher ratio means an increased likelihood of cholesterol deposition in arteries, leading to atherosclerosis and a higher risk of cardiovascular disease.

A prospective cohort study by Xiao et al indicated that as a risk factor, the Apo-B/Apo-A1 ratio is more strongly associated with abdominal aortic aneurysm (AAA) then with coronary heart disease (CHD), despite the relationship of both conditions to atherosclerosis. In addition, Apo-A1 was found to have a greater protective effect against AAA than CHD. [7]

A study by Henson et al indicated that in patients with coronary artery disease, low levels of immune complex consisting of Apo-A1 and immunoglobulin G (IgG) are an independent risk factor for adverse cardiovascular events. Thus, according to the investigators, this immune complex may represent a potential biomarker for predicting cardiovascular disease progression. [8]

Apo-A1 is one of many serum markers used in the fibroTest, a noninvasive assessment of the liver that was validated in many liver disease, including hepatitis C, hepatitis B, nonalcoholic fatty liver disease, and alcoholic liver disease.

Considerations

Serum Apo-A1 is not considered a routine test for cardiovascular disease risk assessment.

Overnight fasting might not be necessary to evaluate apo-A1, but most of the laboratories still commend it.

Apo-A1 Milano is a naturally occurring mutant of Apo-A1 associated with a very low HDL level but apparent longevity and much less atherosclerosis than expected for their HDL-C levels. [9]

A defect in the Apo-A1 gene (APOA1) can cause HDL deficiency and systemic nonneuropathic amyloidosis.

Previous
Next: